The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
Lindsten, T., Ross, A. J., King, A., Zong, W.-X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00136-2 · Cited by 1,489
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
Self-citationKuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185
Mcl-1 deficiency results in peri-implantation embryonic lethality
Rinkenberger, J. L., Horning, S., Klocke, B., Roth, K., & Korsmeyer, S. J. (2000) · Genes & Development · doi:10.1101/gad.14.1.23 · Cited by 397
Research works printed but not linked: 53
- Baell, 2002, Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs, Biochem. Pharmacol., 64, 851, 10.1016/S0006-2952(02)01148-6 · DOI
- Brummelkamp, 2002, Stable suppression of tumorigenicity by virus-mediated RNA interference, Cancer Cell, 2, 243, 10.1016/S1535-6108(02)00122-8 · DOI · Paper page
- Chan, 2003, Identification of chelerythrine as an inhibitor of Bcl-xL function, J. Biol. Chem., 278, 20453, 10.1074/jbc.C300138200 · DOI
- Chen, 2005, Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function, Mol. Cell, 17, 393, 10.1016/j.molcel.2004.12.030 · DOI · Paper page
- Cheng, 2001, Bcl-2, Bcl-xL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis, Mol. Cell, 8, 705, 10.1016/S1097-2765(01)00320-3 · DOI
- Cochran, 2001, Protein-protein interfaces: Mimics and inhibitors, Curr. Opin. Chem. Biol., 5, 654, 10.1016/S1367-5931(01)00262-9 · DOI
- Cory, 2003, The Bcl-2 family: Roles in cell survival and oncogenesis, Oncogene, 22, 8590, 10.1038/sj.onc.1207102 · DOI
- Craig, 2002, Mcl-1 provides a window on the role of the Bcl-2 family in cell proliferation, differentiation and tumorigenesis, Leukemia, 16, 444, 10.1038/sj.leu.2402416 · DOI · Paper page
- Cuconati, 2003, DNA damage response and Mcl-1 destruction initiate apoptosis in adenovirus-infected cells, Genes Dev., 17, 2922, 10.1101/gad.1156903 · DOI
- Degterev, 2001, Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL, Nat. Cell Biol., 3, 173, 10.1038/35055085 · DOI
- Ekert, 2004, Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die, J. Cell Biol., 165, 835, 10.1083/jcb.200312031 · DOI
- Enyedy, 2001, Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening, J. Med. Chem., 44, 4313, 10.1021/jm010016f · DOI
- Fesik, 2005, Promoting apoptosis as a strategy for cancer drug discovery, Nat. Rev. Cancer, 5, 876, 10.1038/nrc1736 · DOI
- Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
- Huang, 2000, BH3-only proteins—Essential initiators of apoptotic cell death, Cell, 103, 839, 10.1016/S0092-8674(00)00187-2 · DOI · Paper page
- Huang, 1997, Bcl-2, Bcl-xL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death, Oncogene, 14, 405, 10.1038/sj.onc.1200848 · DOI
- Huang, 1997, The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry, EMBO J., 16, 4628, 10.1093/emboj/16.15.4628 · DOI
- Huang, 2000, Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways, Blood, 96, 1764, 10.1182/blood.V96.5.1764 · DOI
- Jeffers, 2003, Puma is an essential mediator of p53-dependent and -independent apoptotic pathways, Cancer Cell, 4, 321, 10.1016/S1535-6108(03)00244-7 · DOI
- Johnstone, 2002, Apoptosis: A link between cancer genetics and chemotherapy, Cell, 108, 153, 10.1016/S0092-8674(02)00625-6 · DOI
- Jourdan, 2003, A major role for Mcl-1 anti-apoptotic protein in the IL-6-induced survival of human myeloma cells, Oncogene, 22, 2950, 10.1038/sj.onc.1206423 · DOI
- Kaufmann, 2003, Alterations in the apoptotic machinery and their potential role in anticancer drug resistance, Oncogene, 22, 7414, 10.1038/sj.onc.1206945 · DOI
- Kitada, 2000, Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate anti-apoptosis proteins in B-cell chronic lymphocytic leukemia, Blood, 96, 393, 10.1182/blood.V96.2.393 · DOI · Paper page
- Kitada, 2003, Discovery, characterisation, and structure-activity relationships studies of pro-apoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins, J. Med. Chem., 46, 4259, 10.1021/jm030190z · DOI · Paper page
- Kozopas, 1993, mcl-1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to bcl-2, Proc. Natl. Acad. Sci. USA, 90, 3516, 10.1073/pnas.90.8.3516 · DOI · Paper page
- Le Gouill, 2004, VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis, Blood, 104, 2886, 10.1182/blood-2004-05-1760 · DOI
- Liu, 2003, The structure of a Bcl-xL/Bim fragment complex: Implications for Bim function, Immunity, 19, 341, 10.1016/S1074-7613(03)00234-6 · DOI
- MacCallum, 2005, Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1, Cancer Res., 65, 5399, 10.1158/0008-5472.CAN-05-0233 · DOI · Paper page
- Nijhawan, 2003, Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation, Genes Dev., 17, 1475, 10.1101/gad.1093903 · DOI · Paper page
- O'Connor, 1998, Bim: A novel member of the Bcl-2 family that promotes apoptosis, EMBO J., 17, 384, 10.1093/emboj/17.2.384 · DOI
- Oltersdorf, 2005, An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, 435, 677, 10.1038/nature03579 · DOI · Paper page
- Opferman, 2005, Obligate role of anti-apoptotic Mcl-1 in the survival of hematopoietic stem cells, Science, 307, 1101, 10.1126/science.1106114 · DOI
- Petros, 2000, Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies, Protein Sci., 9, 2528, 10.1017/S096183680000331X · DOI
- Rahmani, 2005, Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation, J. Biol. Chem., 280, 35217, 10.1074/jbc.M506551200 · DOI · Paper page
- Raje, 2005, Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma, Blood, 106, 1042, 10.1182/blood-2005-01-0320 · DOI
- Ranger, 2001, Mouse models of cell death, Nat. Genet., 28, 113, 10.1038/88815 · DOI · Paper page
- Rutledge, 2002, A view to a kill: Ligands for Bcl-2 family proteins, Curr. Opin. Chem. Biol., 6, 479, 10.1016/S1367-5931(02)00352-6 · DOI
- Sattler, 1997, Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis, Science, 275, 983, 10.1126/science.275.5302.983 · DOI · Paper page
- Schmitt, 2000, Genetic analysis of chemoresistance in primary murine lymphomas, Nat. Med., 6, 1029, 10.1038/79542 · DOI · Paper page
- Shibue, 2003, Integral role of Noxa in p53-mediated apoptotic response, Genes Dev., 17, 2233, 10.1101/gad.1103603 · DOI · Paper page
- Strasser, 1990, Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2, Nature, 348, 331, 10.1038/348331a0 · DOI · Paper page
- Su, 2002, Large-scale analysis of the human and mouse transcriptomes, Proc. Natl. Acad. Sci. USA, 99, 4465, 10.1073/pnas.012025199 · DOI · Paper page
- Tsujimoto, 1985, Involvement of the bcl-2 gene in human follicular lymphoma, Science, 228, 1440, 10.1126/science.3874430 · DOI
- Tzung, 2001, Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3, Nat. Cell Biol., 3, 183, 10.1038/35055095 · DOI · Paper page
- Vaux, 1988, Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells, Nature, 335, 440, 10.1038/335440a0 · DOI · Paper page
- Wang, 2000, Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells, Proc. Natl. Acad. Sci. USA, 97, 7124, 10.1073/pnas.97.13.7124 · DOI · Paper page
- Waterhouse, 2004, Assaying cytochrome c translocation during apoptosis, Methods Mol. Biol., 284, 307
- Willis, 2005, Pro-apoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins, Genes Dev., 19, 1294, 10.1101/gad.1304105 · DOI · Paper page
- Yu, 2005, The role of Mcl-1 down-regulation in the pro-apoptotic activity of the multikinase inhibitor BAY 43-9006, Oncogene, 24, 6861, 10.1038/sj.onc.1208841 · DOI
- Zhai, 2006, Comparison of chemical inhibitors of anti-apoptotic Bcl-2-family proteins, Cell Death Differ., 13, 1419, 10.1038/sj.cdd.4401937 · DOI
- Zhang, 2002, Myeloid cell factor-1 is a critical survival factor for multiple myeloma, Blood, 99, 1885, 10.1182/blood.V99.6.1885 · DOI
- Zhong, 2005, Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis, Cell, 121, 1085, 10.1016/j.cell.2005.06.009 · DOI
- Zong, 2001, BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak, Genes Dev., 15, 1481, 10.1101/gad.897601 · DOI
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Self-citationABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis
McArthur, K., Whitehead, L. W., Heddleston, J. M., Li, L., Padman, B. S., Oorschot, V., Geoghegan, N. D., Chappaz, S., Davidson, S., San Chin, H., et al. (2018) · Science · doi:10.1126/science.aao6047 · Cited by 1,072
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031
Self-citationRole of BNIP3 and NIX in cell death, autophagy, and mitophagy
Zhang, J., & Ney, P. A. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.16 · Cited by 1,021
Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production
White, M. J., McArthur, K., Metcalf, D., Lane, R. M., Cambier, J. C., Herold, M. J., van Delft, M. F., Bedoui, S., Lessene, G., Ritchie, M. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.036 · Cited by 983
Self-citationFrom basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., et al. (2010) · Nature · doi:10.1038/nature08646 · Cited by 628
Self-citationThe BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603
Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Adams, J. M., & Cory, S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.161 · Cited by 530
Self-citationAgeing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
Blombery, P., Anderson, M. A., Gong, J.-N., Thijssen, R., Birkinshaw, R. W., Thompson, E. R., Teh, C. E., Nguyen, T., Xu, Z., Flensburg, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1119 · Cited by 434
Self-citationCaenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
Self-citationMany players in BCL-2 family affairs
Moldoveanu, T., Follis, A. V., Kriwacki, R. W., & Green, D. R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.006 · Cited by 421
The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
Stewart, M. L., Fire, E., Keating, A. E., & Walensky, L. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.391 · Cited by 418
Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens
Najm, F. J., Strand, C., Donovan, K. F., Hegde, M., Sanson, K. R., Vaimberg, E. W., Sullender, M. E., Hartenian, E., Kalani, Z., Fusi, N., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4048 · Cited by 279
EGFR family: Structure physiology signalling and therapeutic targets †
Burgess, A. W. (2008) · Growth Factors · doi:10.1080/08977190802312844 · Cited by 288
VDAC2 enables BAX to mediate apoptosis and limit tumor development
Chin, H. S., Li, M. X., Tan, I. K. L., Ninnis, R. L., Reljic, B., Scicluna, K., Dagley, L. F., Sandow, J. J., Kelly, G. L., Samson, A. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07309-4 · Cited by 196
Self-citationUnleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2615 · Cited by 185
Self-citationBasu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171
Senescence and senotherapeutics: a new field in cancer therapy
Myrianthopoulos, V., Evangelou, K., Vasileiou, P. V. S., Cooks, T., Vassilakopoulos, T. P., Pangalis, G. A., Kouloukoussa, M., Kittas, C., Georgakilas, A. G., & Gorgoulis, V. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.006 · Cited by 160
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Rational Design of Proteolytically Stable, Cell-Permeable Peptide-Based Selective Mcl-1 Inhibitors
Muppidi, A., Doi, K., Edwardraja, S., Drake, E. J., Gulick, A. M., Wang, H.-G., & Lin, Q. (2012) · Journal of the American Chemical Society · doi:10.1021/ja306864v · Cited by 156
Faber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411848112 · Cited by 127
Lindner, A. U., Concannon, C. G., Boukes, G. J., Cannon, M. D., Llambi, F., Ryan, D., Boland, K., Kehoe, J., McNamara, D. A., Murray, F., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2269 · Cited by 105
Anticancer Drugs Targeting the Mitochondrial Electron Transport Chain
Rohlena, J., Dong, L.-F., Ralph, S. J., & Neuzil, J. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3990 · Cited by 91
Nangia, V., Siddiqui, F. M., Caenepeel, S., Timonina, D., Bilton, S. J., Phan, N., Gomez-Caraballo, M., Archibald, H. L., Li, C., Fraser, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0277 · Cited by 94
Targeting MCL-1 protein to treat cancer: opportunities and challenges
Tantawy, S. I., Timofeeva, N., Sarkar, A., & Gandhi, V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1226289 · Cited by 90
Small molecule modulators of protein-protein interactions: selected case studies
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79
Cellular senescence in the aging brain: A promising target for neurodegenerative diseases
Sahu, M. R., Rani, L., Subba, R., & Mondal, A. C. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111675 · Cited by 75
Allosteric inhibition of antiapoptotic MCL-1
Lee, S., Wales, T. E., Escudero, S., Cohen, D. T., Luccarelli, J., Gallagher, C. G., Cohen, N. A., Huhn, A. J., Bird, G. H., Engen, J. R., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3223 · Cited by 59
Sale, M. J., & Cook, S. J. (2013) · Biochemical Journal · doi:10.1042/bj20121212 · Cited by 58
Inflammation and survival pathways: Chronic lymphocytic leukemia as a model system
Chen, L. S., Balakrishnan, K., & Gandhi, V. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.039 · Cited by 55
Self-citationHoffman-Luca, C. G., Ziazadeh, D., McEachern, D., Zhao, Y., Sun, W., Debussche, L., & Wang, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2506 · Cited by 52
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
Wade, M., Rodewald, L. W., Espinosa, J. M., & Wahl, G. M. (2008) · Cell Cycle · doi:10.4161/cc.7.13.6072 · Cited by 48
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
BIM-mediated membrane insertion of the BAK pore domain is an essential requirement for apoptosis
Weber, K., Harper, N., Schwabe, J., & Cohen, G. M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.010 · Cited by 41
Kasper, S., Breitenbuecher, F., Reis, H., Brandau, S., Worm, K., Köhler, J., Paul, A., Trarbach, T., Schmid, K. W., & Schuler, M. (2013) · Oncogene · doi:10.1038/onc.2012.302 · Cited by 35
Gabriel, S. S., Bon, N., Chen, J., Wekerle, T., Bushell, A., Fehr, T., & Cippà, P. E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00073 · Cited by 20
Vo, D. D., Gautier, F., Juin, P., & Grée, R. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.02.036 · Cited by 14
Wang, Z., Guo, K., Gao, P., Pu, Q., Wu, M., Li, C., & Hur, J. (2020) · arXiv · doi:10.48550/arxiv.2005.07856 · Cited by 9
Tsou, L. K., Cheng, Y., & Cheng, Y.-C. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.04.004 · Cited by 10
Metadata
- Authors
- van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., Adams, J. M., Roberts, A. W., & Huang, D. C. S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 10
- Issue
- 5
- Pages
- 389-399
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2027395744
- Cited by
- 1,240
- References
- 7
- FWCI
- 24.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2450 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.